Status:
ACTIVE_NOT_RECRUITING
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Mucormycosis
Hematologic Malignancies
Eligibility:
All Genders
18-75 years
Brief Summary
The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and economic burden of mucormycosis in a Chin...
Detailed Description
Divide the patients into pre-covid 19 group(2015.01-2019.12) and covid 19 group(2020.1-2023.12) according to the time period. Objectives: 1.Conduct a comparative analysis in 2015-2020 stage (Pre-Cov...
Eligibility Criteria
Inclusion
- Patients with hematologic diseases who undergoes hematopoietic stem cell transplantation in the center from January 2015 to December 2023.
- Age≥18 years old.
- Patients who were diagnosed with mucormycosis(proven or probable) in accordance with the 2008 EORTC/MSG criteria and Revised EORTC/MSGERC 2020 Criteria.\[8\]\[9\].
- The patients themselves or their authorized clients agree to participate in the clinical study and sign the informed consent.
Exclusion
- 1\. Patients with fungal infections other than mucormycosis were excluded.
Key Trial Info
Start Date :
October 7 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06900114
Start Date
October 7 2023
End Date
October 31 2025
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China